SUMMIT (dpa-AFX) - Celgene International Sàrl, a wholly owned subsidiary of Celgene Corp. (CELG), said the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for continuous oral treatment with REVLIMID in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation.
The CHMP reviews applications for all 28 member states in the European Union, as well as Norway, Liechtenstein and Iceland.
The European Commission, which generally follows the recommendation of the CHMP, is expected to make its final decision in about two months.
Multiple myeloma is a persistent and life-threatening blood cancer, characterized by tumor proliferation and suppression of the immune system. On average, multiple myeloma is diagnosed between 65-74 years of age.
REVLIMID is not currently indicated for the treatment of newly diagnosed multiple myeloma in any country.
Copyright RTT News/dpa-AFX